Gefitinib

Product introduction:

Gefitinib is an anti-tumor targeted drug with high specificity. It is the first molecular targeted drug for the treatment of non-small cell lung cancer. It plays a role by selectively inhibiting the signal transduction pathway of epidermal growth factor receptor tyrosine kinase (EGFR-TK). Epidermal growth factor (EGF) is a relative molecular weight of 6.45 × The polypeptide of 103 can bind to epidermal growth factor receptor (EGFR) on the target cell membrane to produce biological effects. EGFR is a tyrosine kinase (TK) receptor. When combined with EGF, it can promote TK activation in the recipient, lead to self phosphorylation of receptor tyrosine residues, provide continuous division signal to the cell, and cause cell proliferation and differentiation. EGFR is abundant in human tissues and highly expressed in malignant tumors. Gefitinib blocks EGFR signal transduction pathway on cell surface, hinders tumor growth, metastasis and angiogenesis, and can induce tumor cell apoptosis.

CAS：184475-35-2

Molecular formula: C₂₂H₂₄ClFN₄O₃

Molecular weight: 446.9

Structural type:

Product purpose: An inhibitor of epidermal growth factor receptor lysine kinase (EGFR TK). For the treatment of non stem cell lung cancer. But the side effects are great.